Edesa Biotech, Inc. (NASDAQ:EDSA) is developing EB05 (paridiprubart) as a treatment for acute respiratory distress syndrome (ARDS). The drug is currently being evaluated in a Phase 3 clinical ...

Fred Ards doesn’t say a lot. The No. 1 player in the debut of the Sentinel’s 2027 Central Florida Super60 says he likes to do his talking on the field. “I don’t really talk on the field ...

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational ...

Acute Respiratory Distress Syndrome (ARDS) is a condition that can develop as a severe complication of pneumonia, sepsis, or trauma resulting in life-threatening lung injury with fluid leakage ...

Background: Over the last decade, several studies have suggested that survival rates for patients with acute lung injury (ALI) or ARDS may have improved. We performed a systematic analysis of the ...

Opens in a new tab or window HONOLULU -- As suspected, patients with acute respiratory distress syndrome (ARDS) had particularly bad outcomes if they had coexisting pulmonary hypertension (PH), an ...

New cell therapy shows promise with ARDS patients Initial trial suggests invariant natural killer cell therapy improves survival Date: February 6, 2024 Source: Anglia Ruskin University Summary: An ...

The report, which builds on the 2012 Berlin Definition of ARDS, will be published Jan. 1, 2024 in the American Thoracic Society's AJRCCM. ARDS is a life-threatening illness in which the lungs are ...

Data were obtained for 13,505 hospitalized children ages 28 days to 18 years from the IBM MarketScan commercial and Medicaid databases (2013 to 2017) who received mechanical ventilation and had ...